Tekton by
the numbers
340,000
Patient database
900+
Trials conducted
9
Strategic CRO partnerships
25
Sites across
9 states
35+
Sub-Investigators
30
Investigators
25,000+
Participants enrolled
Designed for Performance
A Network Built Around Practicing Physicians
1.5 DAYS
Average site activation to FPI for vaccine trials
5.9 DAYS
average to FPI for cardiometabolic & neuroscience
116%
Average
enrollment rate
95%
Participant
retention
The Practicing Physician Advantage
Tekton’s multi-specialty hub model connects multi-specialty practicing physicians to shared, research-dedicated clinics supported by centralized regulatory, recruitment, and operations teams.
This structure allows:
-
Faster startup
-
Stronger cross-referrals
-
Shared infrastructure
-
Consistent quality standards
It also reflects how patients actually receive care – through trusted physicians embedded in their communities.
76%
of patients expect to hear about clinical trials from their treating physician.
77%
Cite trust in their physician as a reason to participate in a clinical trial.
Case Studies
Targets surpassed
Tekton exceeded enrollment targets across all 3 sites in a Type 1 Diabetes trial, with our McKinney, TX site more than doubling its goal—prompting the sponsor to spotlight our team as a model for best practices.
Rapid Enrollment, Record Results
Tekton delivered 172% average enrollment across 7 sites, for a total of >720 patients for a 2024 Global Phase 3 vaccine clinical trial.
Accelerated Enrollment
Tekton Research sites averaged just 1 day from activation to first patient visit for a phase 3 norovirus vaccine trial, with 3 of 7 sites achieving this milestone in under 24 hours.
Setting the Pace: First Patient In
Tekton Research led the way in an Alzheimer’s Disease trial by enrolling the study’s first patient, surpassing enrollment goals and contributing to protocol design.
Browse All Case Studies
Case Study: GLP-1 Medication Research Study
Tekton met enrollment goals for a GLP-1 study in Moore, OK three months early, with a one-day regulatory turnaround.
Case Study: Phase 2 Migraine Research Study
Tekton delivered a Phase 2 migraine study in Yukon, OK with 100% patient retention and a 1.5-day regulatory turnaround.
Case Study: Achieving 120% of Enrollment Targets for a Teen Cytomegalovirus (CMV) Trial at 5 Sites
Tekton achieved an average of 172% enrollment across three sites, enrolling more than 30 patients in a recent Type 1 Diabetes clinical trial.
Case Study: Advancing Glucose Monitoring for Pregnant Women with Diabetes
Tekton reached 240% of enrollment goals, enrolling 12 patients in a CGM study for pregnant women with diabetes.
Study Performance: Achieving 172% of Enrollment Targets for a Type 1 Diabetes Trial at 3 Sites
Tekton averaged 172% enrollment across three sites, enrolling 30+ patients in a Type 1 Diabetes clinical trial.
Study Performance: Accelerating Alzheimer’s Disease Research
Tekton Research averaged a one-day turnaround from site activation to first patient visit across seven sites in a recent Phase 3 norovirus vaccine trial.
Case Study: Fast-Tracking Enrollment for a Global Phase 3 Norovirus Vaccine Trial
Tekton Research achieved an average of one day from site activation to first patient visit across seven sites in a Phase 3 norovirus vaccine trial.
Case Study: Achieving 172% of Enrollment Targets for a Global Phase 3 Trial
Tekton achieved an average of 172% enrollment across seven sites, enrolling more than 720 patients in a 2024 Global Phase 3 vaccine clinical trial.
Partner With Us
Join the leading sponsors and CROs who trust Tekton Research with their most important neurology, CNS, psychiatry, and general medicine clinical trials. Contact us today to discuss how our specialized expertise can help bring your next breakthrough treatment to patients in need.